Rankings
▼
Calendar
AKBA FY 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AKBA
Akebia Therapeutics, Inc.
$365M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$160M
-17.7% YoY
Gross Profit
$97M
60.6% margin
Operating Income
-$50M
-31.5% margin
Net Income
-$69M
-43.3% margin
EPS (Diluted)
$-0.33
Cash Flow
Operating Cash Flow
-$41M
Free Cash Flow
-$41M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$221M
Total Liabilities
$270M
Stockholders' Equity
-$49M
Cash & Equivalents
$52M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$160M
$195M
-17.7%
Gross Profit
$97M
$120M
-19.5%
Operating Income
-$50M
-$46M
-9.1%
Net Income
-$69M
-$52M
-33.7%
← Q4 2023
All Quarters
Q1 2024 →